Effects of mycophenolate mofetil for patients with crescentic lupus nephritis

Nephrology

Volumn 13, Issue 8, 2008, Pages 702-707

  Tang, Zheng ^a,b   Yang, Guang ^a   Yu, Chen ^a   Yu, Yusheng ^a   Wang, Jinquan ^a   Hu, Weixin ^a   Zeng, Caihong ^a   Chen, Huiping ^a   Liu, Zhihong ^a   Li, Leishi ^a  

^a NANJING UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

Crescentic glomerulonephritis; Cyclophosphamide; Immunosuppressor; Lupus nephritis; Mycophenolate mofetil

Indexed keywords

CYCLOPHOSPHAMIDE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HERPES; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; LEUKOPENIA; LIVER INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; BIOPSY; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MALE; MYCOPHENOLIC ACID; PULSE THERAPY, DRUG; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 58149107325     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2008.00975.x     Document Type: Article

References (22)

1. Tang Z, Wu Y, Wang QW et al. Clinical spectrum of diffusecrescentic glomerulonephritis in Chinese patients. Chin. Med. J. 2003 116 : 1737 40.
2. Chen HP, Tang Z, Zeng CH et al. Pathological demography of native patients in a nephrology center in China. Clin. Med. J. 2003 116 : 1377 81.
3. Nchman PH, Dooley MA, Hogan S, Jennette C, Falk R. Mycophenolate mofetil therapy in patients with cyclophosphamide resistant or relapsing diffuse proliferative lupus nephritis. Am. J. Soc. Nephrol. 1997 8 : 448A.
4. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am. J. Kidney Dis. 1998 32 : 318 26.
5. Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM. Lupus nephritis: Treatment with mycophenolate mofetil. Rhematology (Oxford) 2004 43 : 377.
6. Cross J, Dwomoa A, Andrews P et al. Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron. Clin. Pract. 2005 100 : c92 100.
7. My K, Alba P, Cuadrado MJ. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rhematology (Oxford) 2002 41 : 876.
8. Illei GG, Austin HA, Crane M et al. Combination therapy with pulse cyclophosphamide plus pulse methyloprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Intern. Med. 2001 135 : 248.
9. Falk RJ, Jennette C, Nachman PH. Rapidly progressive glomerulonephritis and crescentic glomerulonephritis. In Brenner BM (ed Brenner & Recto's The Kidney, Vol. II, 6th edn Oversea Publishing House : WB Sunders Company, 2000 1313 21.
10. Sumethkul V, Chalermsanyakorn P, Changsirikulchai S, Radinahamed P. Lupus nephritis: A challenging cause of rapidly progressive crescentic glomerulonephritis. Lupus 2000 9 : 424 8.
11. Austin HA, III., Kilppel JH, Balow JE, Boumpas DT, Vaughan EM. Therapy of lupus nephritis: Controlled trial of prednisone and toxic drugs. N. Engl. J. Med. 1996 314 : 614 23.
12. Illei GC, Austin HA, Crane M. Combination therapy with pulse cyclophosphomide plus pulse methylprednisone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann. Intern. Med. 2001 135 : 248.
13. Cameron JS. Lupus nephritis. J. Am. Soc. Nephrol. 1999 10 : 413 19.
14. Appel GB, Radhakrishnan J, Ginzler EM. Use of mycophenolate mofetil in autoimmune and renal diseases. Transplantation 2005 80 : s265 271.
15. Nieto E, Escudero E, Navarro E et al. Effects of mycophenolate mofetil in mercury-induced autoimmune nephritis. J. Am. Soc. Nephrol. 2002 13 : 937 45.
16. Allison AC, Eugui EM. Mycophenolate mofetil and its machenism of action. Immunopharmacology 2000 47 : 85 93.
17. Halloran P, Mathew T, Tomlanovitch S, Groth C, Hooftman L, Barker C. For the International Mycophenolate Mofetil Renal Transplantant Study Groups. Mycophenolate mofetil in renal graft recipients: A pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. Transplantation 1997 63 : 39 48.
18. Pisoni CN, Sanchez FJ, Karim Y et al. Mycophenolate mofetil in systemic lupus erythematosus: Efficacy and tolerability in 86 patients. J. Rheumatol. 2005 32 : 967 70.
19. Dooley MA, Cosio FG, Facchinetti D. Mycophenolate mofetil therapy in lupus nephritis: Clinical observations. J. Am. Soc. Nephrol. 1999 10 : 833.
20. Riskalla MM, Somers EC, Fatica RA, McCune WJ. Tolerability of mycophenolate mofetil patients with systemic lupus erythematosus. J. Rheumatol. 2003 30 : 1508.
21. Hu WX, Liu ZH, Chen HP, Tang Z. Mycophenolate mofetil versus cyclophosphamide (IVC) therapy for patients with diffuse proliferative lupus nephritis. Chin. Med. J. 2002 115 : 705.
22. Chan TM, Tse KC, Tang CS. Long-term study of Mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J. Am. Soc. Nephrol. 2005 10 : 1076.